HIGHLIGHTS
- who: Liliana Raimundo and collaborators from the (UNIVERSITY) have published the Article: Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target, in the Journal: Cancers 2021, 13, 3438. of 14/05/2021
- what: Despite numerous studies with the aforementioned DDR inhibitors, only PARPi have been approved by the FDA for clinical use.
- how: In fact the pharmacological advantage of induced synthetic lethality has been extenpatients were tested in clinical trials for their therapeutic response to the PARPi olaparib . sively during the last decades particularly with PARPi.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.